<DOC>
	<DOCNO>NCT02435433</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ramucirumab participant hepatocellular carcinoma ( HCC ) elevate baseline alpha-fetoprotein . Participants randomize ramucirumab placebo 2:1 ratio .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Versus Placebo Participants With Hepatocellular Carcinoma Elevated Baseline Alpha-Fetoprotein</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>A diagnosis HCC base histopathologic finding , diagnosis cirrhosis tumor classical HCC image characteristic . Prior sorafenib treatment least 14 day discontinuation sorafenib ≥14 day prior randomization . Radiographic disease progression sorafenib therapy discontinuation sorafenib intolerance . Sorafenib systemic therapy HCC . ≥1 measurable lesion per Response Evaluation Criteria In Solid Tumors ( RECIST ) Version 1.1 previously treat locoregional therapy . A participant lesion ( ) previously treat locoregional therapy also eligible , lesion document progression locoregional treatment measureable . ChildPugh score &lt; 7 ( ChildPugh Class A ) . Barcelona Clinic Liver Cancer ( BCLC ) Stage C disease BCLC Stage B disease amenable locoregional therapy refractory locoregional therapy . Baseline AFP ≥400 nanograms/milliliter . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Resolution clinically significant toxic effect prior therapy . Total bilirubin ≤1.5 time upper limit normal value ( ULN ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤5 × ULN . Creatinine clearance ≥60 milliliters/minute . Urinary protein ≤1+ dipstick routine urinalysis 24hour urine demonstrate &lt; 1 gram protein . Absolute neutrophil count ≥1.0 × 10^9/Liter , hemoglobin ≥9 grams/deciliter , platelet ≥75 × 10^9/Liter . International Normalized Ratio ( INR ) ≤1.5 partial thromboplastin time ( PTT ) ≤5 second ULN . Surgically sterile , postmenopausal , compliant highly effective contraceptive method . If woman childbearing potential , negative serum pregnancy test prior randomization . Willing provide blood research . Fibrolamellar carcinoma mixed hepatocellular cholangiocarcinoma . Concurrent malignancy . Participants carcinoma situ origin participant prior malignancy remission may eligible sponsor approval . Previous brain metastasis , leptomeningeal disease , uncontrolled spinal cord compression . History current hepatic encephalopathy clinically meaningful ascites . Ongoing recent hepatorenal syndrome . Liver transplant . Previous systemic therapy vascular endothelial growth factor ( VEGF ) pathway inhibitor sorafenib treatment HCC . Hepatic locoregional therapy follow sorafenib within 28 day prior randomization . Major surgical procedure , traumatic injury , nonhealing wound , peptic ulcer ≤28 day prior randomization . Placement subcutaneous venous access device within 7 day prior first dose study treatment unless procedure judge low risk bleeding . Enrolled clinical trial involve investigational product nonapproved use drug medical research judge scientifically medically compatible study . Discontinued study treatment another clinical trial within 28 day prior randomization . Known allergy treatment component . Uncontrolled hypertension . Any arterial thrombotic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack , &lt; 6 month prior randomization . Any bleeding episode consider lifethreatening , Grade 3 4 gastrointestinal bleeding episode 3 month prior randomization require intervention . Esophageal gastric varix require intervention represent high bleeding risk . Participants evidence portal hypertension prior bleed must endoscopic evaluation within 3 month prior randomization . Gastrointestinal perforation fistula within 6 month prior randomization . Symptomatic congestive heart failure ( New York Heart Association IIIV ) , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia . Pregnant breastfeeding . Any medical psychiatric condition may increase risk associate study participation may interfere interpretation study result . Conditions include limit : Human immunodeficiency virus infection acquire immunodeficiency syndromerelated illness . Active uncontrolled clinically serious infection . ( Participants chronic viral hepatitis eligible . ) Ongoing recent history drug abuse . Uncontrolled hereditary acquire thrombotic bleeding disorder . Bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection . Therapeutic dose anticoagulation warfarin , low molecularweight heparin , similar agent . Chronic therapy nonsteroidal antiinflammatory agent antiplatelet agent . Aspirin dose 100 milligrams/day permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>liver cancer</keyword>
</DOC>